ArticleRevista Brasileira de terapia intensiva
Analysis of biofilm production by clinical isolates of Pseudomonas aeruginosa from patients with ventilator-associated pneumonia.
Article in Revista Brasileira de terapia intensiva. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 68 citations in OpenAlex.
- Genetic Determinants Associated With the Biofilm Formation Impairment in Pseudomonas aeruginosa Clinical Isolates.MicrobiologyOpen · 2025Article
- Strategies to facilitate the bioprospection of properties of agronomic interest in microbial culture collections and a successful case of selection to mitigate drought stress in maize.BMC microbiology · 2025Article
- Antimicrobial and anti-biofilm activity of Hypericum brasiliense extract and its fractions on Staphylococcus of canine origin.Scientific reports · 2025Article
- Genetic and virulence factors behind the success of high-riskFrontiers in microbiology · 2025Article
- Vitamin D and vitamin K1 as novel inhibitors of biofilm in Gram-negative bacteria.BMC microbiology · 2024Article
- Olive oil nanoemulsion containing curcumin: antimicrobial agent against multidrug-resistant bacteria.Applied microbiology and biotechnology · 2024Article
- Prevalence of Type III Secretion System (T3SS) and Biofilm Development in Genetically Heterogeneous Clinical Isolates of Pseudomonas aeruginosa from Nigeria.Current microbiology · 2023Article
- Antimicrobial Resistance, Genetic Lineages, and Biofilm Formation inAntibiotics (Basel, Switzerland) · 2023Article
- Phenotypic and genotypic characterization of clinicalJournal of Taibah University Medical Sciences · 2023Article
- Evidence-Based Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Pathogen Burden Among ICU Patients in a Tertiary Care Hospital in Hail Saudi Arabia with Particular Reference to β-Lactamases Profile.Infection and drug resistance · 2023Article
- Prevalence and Virulence of Commensal Pseudomonas Aeruginosa Isolates from Healthy Individuals in Southern Vietnam (2018-2020).Biomedicines · 2022Article
- Novel PCR detection of CRISPR/Cas systems in Pseudomonas aeruginosa and its correlation with antibiotic resistance.Applied microbiology and biotechnology · 2022Article
- Assessment of biofilms formation of bacterial and fungal isolates using qualitative Congo red agar and semiquantitative crystal violet microtiter methodsBiomedica : revista del Instituto Nacional de Salud · 2022Article
- A phenotypic and molecular investigation of biofilm formation in clinical samples ofMolecular biology research communications · 2021Article
- Evaluation of the antioxidant, antibacterial, and antibiofilm activity of the sesquiterpene nerolidol.Archives of microbiology · 2021Article
- Silver nanoparticles-chitosan composites activity against resistant bacteria: tolerance and biofilm inhibition.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2021Article
- Antimicrobial and Antibiofilm Capacity of Chitosan Nanoparticles against Wild Type Strain ofAntibiotics (Basel, Switzerland) · 2020Article
- Novel Aminoglycoside-Tolerant Phoenix Colony Variants of Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2020Article
- Phenotypic and genotypic analysis of biofilm production by Pseudomonas aeruginosa isolates from infection and colonization samples.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo phenotypically evaluate biofilm production by Pseudomonas aeruginosa clinically isolated from patients with ventilator-associated pneumonia.
methodsTwenty clinical isolates of P. aeruginosa were analyzed, 19 of which were from clinical samples of tracheal aspirate, and one was from a bronchoalveolar lavage sample. The evaluation of the capacity of P. aeruginosa to produce biofilm was verified using two techniques, one qualitative and the other quantitative.
resultsThe qualitative technique showed that only 15% of the isolates were considered biofilm producers, while the quantitative technique showed that 75% of the isolates were biofilm producers. The biofilm isolates presented the following susceptibility profile: 53.3% were multidrug-resistant, and 46.7% were multidrug-sensitive.
conclusionThe quantitative technique was more effective than the qualitative technique for the detection of biofilm production. For the bacterial population analyzed, biofilm production was independent of the susceptibility profile of the bacteria, demonstrating that the therapeutic failure could be related to biofilm production, as it prevented the destruction of the bacteria present in this structure, causing complications of pneumonia associated with mechanical ventilation, including extrapulmonary infections, and making it difficult to treat the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.